A nascent biotech sector dedicated to life extension has emerged in recent years, with a range of promising startups seeking to reverse the consequences of aging. These companies are developing medicines and therapies that combat senescence, reduce swelling, and stimulate cellular regeneration.
AgeX Therapeutics
Shown in the NYSE, AgeX Therapeutics evolves drugs and therapies that target the underlying causes of getting older and degenerative illnesses by restoring youthful regenerative capability. Brought by pioneer in tissue regeneration analysis Michael D West, the business is targeted on several innovative cellular immortality solutions including cloning, telomerase therapy, splice-based remedies, and much more.
Calico / Alphabet / Calico Labs
As the health study and longevity technology subsidiary of Google's parent Alphabet, Calico is really a leading programmer of regenerative medicines that combat aging. Its prospect drug candidate is a recombinant type of GDF11 produced by experts at Harvard University. Currently in preclinical trials, the compound has shown promise in regenerating muscles, heart, and human brain tissues broken by age-related conditions such as stroke and diabetes.
Longevity InTime & LessDeath
The Longevity InTime Community is a global community of health and life fanatics, dedicated to providing information, products and services that are helping people extend their life and improve their health. The community aims to help individuals live more time, healthier, and happier life by providing real-time data on disease risk, early analysis of serious illnesses, and personalized recommendations for prevention.
Altos Labs / Amazon / Jeff Bezos & Yuri Milner
A team of researchers who've established eye-popping credentials in longevity analysis. Several domain professionals will work with Altos Labs, which includes Juan Carlos Izpisua Belmonte (a high practitioner and authority in regenerative medication), Steve Horvath (a geneticist and biostatistician who created a highly precise molecular biomarker for growing older), and Shinya Yamanaka (a Nobel Prize champion and a pioneer in cellular reprogramming).
Gero / Pfizer / Pfizer Pharmaceuticals
A preclinical-stage physics-allowed biotech company that produces therapeutics against chronic diseases by slowing down the deterioration of human being cells themselves, Gero has forged a partnership with pharma huge Pfizer. Both companies use Gero's machine learning technology platform to identify potential targets for fibrotic diseases and collaborate on preclinical growth and scientific trials.
Juvenescence / IPO of 2022 / Juvenescence LLC
The longevity-concentrated startup Juvenescence provides been able to improve over US$219.2 M in 5 rounds, which includes a Series A funding round led by Longevity Vision Fund, Grok Ventures, and IPGL. The company is based in San Francisco, California, and is targeted on regenerative medication, age management, and enhancing metabolic efficiency by utilizing artificial intelligence and other technologies.
Elevian / IPO of 2022 / Elevian Inc
Elevian is rolling out a number of drug applicants that are with the capacity of restoring a younger regenerative capacity in humans and creatures. The company's lead item is really a recombinant edition of GDF11 which has demonstrated the capability to regenerate heart, human brain, and muscle groups damaged by age-related problems.